The difference between palbociclib and abeciclib

Palbociclib and Abemaciclib are both CDK4/6inhibitors for breast cancer and are similar but not identical drugs. Palbociclib is a pyrroloimidazole compound, while abeciclib is a pyrroloimidazole-pericyclic compound.

Palbociclib is approved for the treatment of patients with hormone receptor-positive, HER2-negative advanced breast cancer. It is usually used in combination with hormone therapy. It generally needs to be taken orally daily for 21 days, and then stopped for 7 days, forming a 28-day treatment cycle. Abeciclib is also approved for the treatment of patients with hormone receptor-positive, HER2-negative advanced breast cancer. It can be used alone or in combination with other drugs, and can be taken orally daily for continuous use. Common side effects of both include fatigue, nausea, vomiting, diarrhea, and blood problems (such as a decrease in white blood cells and anemia). However, specific adverse effects and severity may vary among individuals.

PalbociclibThe original drug has been launched in China and has been included in medical insurance. Currently, reimbursement is only available to patients who meet the indications. The common specifications100mg*21 pills may cost more than 6,000 yuan per box, while the original drug sold overseas is more expensive. The price of 125mg*21 pills per box may be around 10,000 yuan (the price may fluctuate due to exchange rates). Palbociclib generics are also sold overseas. The ingredients of the drug are basically the same as those sold domestically and abroad, but the price is cheap. For example, the price of a box of 125mg*21 tablets produced by a Bangladesh pharmaceutical factory may be several hundred yuan (the price may fluctuate due to the exchange rate).